SCHEMBL2282785

SCHEMBL2282785

Cc1noc(C)c1-c1c(C=O)c2ccccc2n1-c1ccc(O)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 6/20 0.44
BRD4 O60885 5/20 0.36
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
FTO Q9C0B1 2/20 0.34
USP2 O75604 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
ALOX15 P16050 1/20 0.34
CYP2C19 P33261 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
LMNA P02545 3/20 0.33
TP53 P04637 1/20 0.33
BRD2 P25440 1/20 0.33
BRD3 Q15059 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2147037 0.89 ERN1 (0.36) ERN1BRD4KMT2ANPSR1USP2
SCHEMBL2147040 0.89 ERN1 (0.36) ERN1BRD4KMT2ANPSR1USP2
SCHEMBL2283208 0.88 ERN1 (0.44) ERN1BRD4KMT2ANPSR1USP2
SCHEMBL2146131 0.86 ERN1 (0.41) ERN1BRD4KMT2ANPSR1USP2
SCHEMBL1077582 0.82 HSD17B10 (0.34) ERN1BRD4KMT2ANPSR1FTO
SCHEMBL2288265 0.82 ERN1 (0.49) ERN1BRD4KMT2ANPSR1USP2
SCHEMBL2288869 0.81 ERN1 (0.42) ERN1BRD4KMT2ANPSR1USP2
SCHEMBL1076216 0.80 FTO (0.34) ERN1BRD4KMT2ANPSR1FTO
SCHEMBL2311859 0.80 FTO (0.34) ERN1BRD4KMT2ANPSR1FTO
SCHEMBL1076214 0.80 FTO (0.35) ERN1BRD4KMT2ANPSR1FTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 ERN1 384/4885BRD4 891/4885KMT2A 1814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.